TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients
- PMID: 12608932
- DOI: 10.1046/j.1365-2265.2003.01708.x
TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients
Abstract
Objective: From in vitro studies using cultures of orbital fibroblasts, it has become clear that cytokines play an important role in the orbital inflammation in Graves' ophthalmopathy (GO). Orbital fibroblasts seem to be the key target cells of the autoimmune attack, and they are able to express the TSH receptor (TSH-R). In vivo data on the presence of cytokines in orbital tissues are sparse, and mostly limited to samples obtained from patients with endstage, inactive GO; the same holds true for the presence of the TSH-R. The aim of the present study was to determine whether the cytokine profile and TSH-R expression differ in the active vs. the inactive stage of GO.
Design and measurements: Orbital fat/connective tissue was obtained from six patients with active, untreated GO undergoing emergency orbital decompression, and from 11 patients with inactive GO subjected to rehabilitative decompressive surgery. The mRNA levels of various cytokines and the TSH-R were assessed by real-time polymerase chain reaction (PCR) using the LightCycler. Data are expressed as ratios (unknown mRNA/beta-actin mRNA).
Results: Active GO patients had much higher TSH-R expression than inactive patients: 4/0-24 (median value/range) vs. 0/0-9, P = 0.01. TSH-R expression was related to the Clinical Activity Score (r = 0.595, P = 0.015). Patients with active GO compared to those with inactive GO had higher mRNA levels of the proinflammatory cytokines interleukin-1beta (IL-1beta) (445/153-877 vs. 0/0-455, P = 0.001), IL-6 (1583/968-18825 vs. 559/0-7181, P = 0.01), IL-8 (1422/38-7579 vs. 32/0-1081, P = 0.046) and IL-10 (145/58-318 vs. 27/0-189, P = 0.002). In active GO there also existed a trend towards a predominance of T helper 1 (Th1)-derived cytokines as evident from higher IL-2 (37/0-158 vs. 0/0-68, P = 0.043), interferon-gamma (IFN-gamma) (20/0-79 vs. 0/0-16, P = 0.12) and IL-12 (2.3/0-14.8 vs. 0/0-1.6, P = 0.10) mRNAs. IL-1 receptor agonist (IL-1RA), IL-2 receptor (IL-2R), IL-3, IL-4, IL-5, IL-13, IL-18 and tumour necrosis factor-alpha (TNF-alpha) mRNAs were similar in both groups.
Conclusions: These data show that at the mRNA level, TSH-R expression is largely present only during the active stages of GO. The active phase is characterized by the presence of proinflammatory and Th1-derived cytokines, whereas other cytokines, among them Th2-derived cytokines, do not seem to be linked to a specific stage of GO.
Similar articles
-
Demonstration of thyrotropin receptor mRNA in orbital fat and eye muscle tissues from patients with Graves' ophthalmopathy by in situ hybridization.J Endocrinol Invest. 1999 Apr;22(4):289-95. doi: 10.1007/BF03343558. J Endocrinol Invest. 1999. PMID: 10342363
-
A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.Thyroid. 2010 Jan;20(1):59-65. doi: 10.1089/thy.2009.0278. Thyroid. 2010. PMID: 20017620 Free PMC article.
-
Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.Thyroid. 2010 May;20(5):535-44. doi: 10.1089/thy.2009.0447. Thyroid. 2010. PMID: 20384487
-
Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.Exp Eye Res. 2016 Jan;142:83-91. doi: 10.1016/j.exer.2015.02.007. Exp Eye Res. 2016. PMID: 26675405 Review.
-
Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.Front Endocrinol (Lausanne). 2021 Apr 16;12:654473. doi: 10.3389/fendo.2021.654473. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33935970 Free PMC article. Review.
Cited by
-
Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.J Endocrinol Invest. 2016 Jan;39(1):63-72. doi: 10.1007/s40618-015-0322-7. Epub 2015 Jun 11. J Endocrinol Invest. 2016. PMID: 26062519 Free PMC article.
-
Immunological Aspects of Graves' Ophthalmopathy.Biomed Res Int. 2019 Nov 12;2019:7453260. doi: 10.1155/2019/7453260. eCollection 2019. Biomed Res Int. 2019. PMID: 31781640 Free PMC article. Review.
-
Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.Clin Exp Immunol. 2010 Sep;161(3):436-43. doi: 10.1111/j.1365-2249.2010.04191.x. Clin Exp Immunol. 2010. PMID: 20529087 Free PMC article. Clinical Trial.
-
Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.Clin Endocrinol (Oxf). 2022 Sep;97(3):363-370. doi: 10.1111/cen.14655. Epub 2021 Dec 14. Clin Endocrinol (Oxf). 2022. PMID: 34908176 Free PMC article.
-
A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.Endocrinology. 2014 Feb;155(2):627-34. doi: 10.1210/en.2013-1890. Epub 2013 Dec 3. Endocrinology. 2014. PMID: 24302624 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous